Houston, Texas–(Newsfile Corp. – November 5, 2020) – The psychedelics boom is far out, man.
Over the last few months, Denver, Oakland, and Santa Cruz have legalized the use of psilocybin. Even the Canadian government allowed four terminally ill patients with cancer to receive psilocybin therapy to help ease end-of-life distress. This is the first time in 46 years that an exemption has been given in Canada for patients to access such treatment.
Then, earlier this week, Oregon became the first state to legalize psilocybin in a therapeutic setting. With Measure 109, the psilocybin movement is about overcoming depression, as noted by KATU 2 ABC. In addition, “An estimated 1 in every 5 adults in Oregon is coping with a mental health condition,” 20 doctors and other health care workers wrote in the voters’ pamphlet.
“We support Measure 109 because it provides a new treatment for many that might break through where others fall short.”
Psilocybin May be A Major Breakthrough for Treating Depression
With plenty of clinical trials supporting psychedelic treatments, like psilocybin mushrooms for the treatment of obsessive-compulsive disorder, PTSD, opioid addiction, alcoholism, eating disorders, depression and anxiety, it’s only a matter of time before big pharmaceutical companies begin to invest heavily, and incorporate psychedelics into their own drug pipelines.
In fact, a new study from JAMA Psychiatry found that psilocybin, “Worked better than the usual antidepressant medications,” as noted by NPR.
“The effect was more than four times greater,” added Alan Davis, an author of the study and a faculty member at both Johns Hopkins University. “There was a significant reduction in depression in the immediate-treatment group compared to those in the wait list.”
Better Plant Sciences (CSE: PLNT) (OTC: VEGGF) is Part of the Growing Psilocybin Boom
Better Plant Sciences just announced that its majority owned subsidiary NeonMind Biosciences entered into a definitive agreement with Psygen Labs Inc. for the supply of psilocybin for NeonMind’s planned preclinical, and clinical trials to study the use of a drug product including Psilocybin for the treatment of food cravings and anxiety.
“Psilocybin is known to activate serotonin receptors,” says Dr. William Panenka, lead scientific advisor to NeonMind. “As a neurotransmitter, serotonin helps to relay messages from one area of the brain to another. Serotonin is responsible for some of the drivers which govern eating. We are very interested in furthering studies to test various dosing regimens for NeonMind to see the effects that psilocybin may have on the serotonin receptors that regulate food cravings.”
“Psygen’s mission is to fill a supply gap for restricted drug substances and restricted drug products for use in clinical trials and in pre-clinical research,” says Danny Motyka, CEO of Psygen Labs Inc. “We have brokered supply of various restricted drugs for pre-clinical studies and clinical trials through our relationship with a Licensed Dealer. Psygen is currently building out a commercial manufacturing facility designed for high-volume output of psychedelic drug substances and drug products, filling a niche in the evolving psychedelic medicine ecosystem. Today these psychedelic drug substances are classified as restricted drugs, meaning no recognized medical use in Canada, and we are playing our part in moving those substances to the controlled drugs schedule of the Food and Drug Regulations or otherwise providing compliant access to psilocybin and other psychedelics.”
For more information, visit the company’s website at https://betterplantsciences.com
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
For making specific investment decisions, readers should seek their own advice. Winning Media is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement between Winning Media and Better Plant Sciences Inc., Winning Media has been paid two thousand dollars for advertising and marketing services for Better Plant Sciences Inc. We own ZERO shares of Better Plant Sciences Inc. Please click here for full disclaimer.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/67552